Octreotide vs PT-141
Overview
Octreotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Octreotide and PT-141 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Octreotide | PT-141 | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) | 1.75 mg |
| Frequency | Every 4 weeks (LAR); two to four times daily (immediate-release) | as needed |
| Reported benefits | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers | Enhanced libido, improved sexual function, arousal support |
| Reported side effects | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain | Nausea, flushing, blood pressure changes |
Key differences
Primary use. Octreotide is categorised under Hormonal, while PT-141 falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Octreotide: FDA-approved. PT-141: FDA-approved.
Dosing. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)). PT-141 is typically dosed at 1.75 mg (as needed).
Can you stack them?
Some protocols combine peptides, but stacking Octreotide and PT-141 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Octreotide and PT-141?
- Octreotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Octreotide is FDA-approved for one or more indications, whereas PT-141 is FDA-approved for one or more indications.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- What is PT-141 used for?
- Sexual function peptide.
- Can you take Octreotide and PT-141 together?
- Some users combine peptides within a single protocol, but stacking Octreotide and PT-141 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Octreotide or PT-141 FDA-approved?
- Octreotide is FDA-approved for one or more indications. PT-141 is FDA-approved for one or more indications.
Read the full articles
- Octreotide — full monograph: mechanism, research, dosing & references
- PT-141 — full monograph: mechanism, research, dosing & references